NCT03999749 2026-03-09
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
Phase 2 Active not recruiting
NYU Langone Health
Hoffmann-La Roche
Takeda
Weill Medical College of Cornell University
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center